Abbott Reports 7.4% Sales Growth in Q2 2025

By Tamara Parker • Thursday, July 17 15:37 • Permanent Link

Abbott Reports Second-Quarter 2025 Results

Abbott has reported a 7.4% growth in sales for the second quarter of 2025, with organic sales growing by 6.9% or 7.5% excluding COVID-19 testing-related sales. The company's GAAP diluted EPS for the quarter was $1.01, while adjusted diluted EPS stood at $1.26, reflecting double-digit growth compared to the prior year.

For the first half of 2025, Abbott saw a 5.7% increase in reported sales, with organic sales growing by 6.9% or 7.9% when excluding COVID-19 testing-related sales. The company projects full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, to be 7.5% to 8.0%, or 6.0% to 7.0% when including COVID-19 testing-related sales.

In the nutrition business, worldwide sales increased by 2.9% on a reported basis and 3.4% on an organic basis in the second quarter. The adult nutrition segment led the growth, with sales increasing by 6.1% on a reported basis and 6.6% on an organic basis.

In the diagnostics segment, global sales decreased by 1.0% on a reported basis and 1.4% on an organic basis, but increased by 0.8% when excluding COVID-19 testing-related sales. COVID-19 testing-related sales were $55 million in the quarter, compared to $102 million in the second quarter of the prior year.

Abbott's established pharmaceuticals segment saw a 6.9% increase in reported sales and a 7.7% increase in organic sales in the second quarter, with key emerging markets driving the growth.

The medical devices segment experienced a 13.4% increase in reported sales and a 12.2% increase in organic sales in the second quarter. Sales growth in this segment was led by double-digit growth in diabetes care, heart failure, structural heart, and electrophysiology.

The market has reacted to these announcements by moving the company's shares -7.85% to a price of $121.40. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.